Carl Zeiss Meditec Reports Solid Fiscal Year 2024/25 Performance

Carl Zeiss Meditec AG has announced a notable fiscal year 2024/25 performance, showcasing solid revenue growth and a slight increase in EBITA. The company's revenue reached EUR 2,228 million, marking a 7.8% rise compared to the previous year. Meanwhile, EBITA improved to EUR 257.7 million from EUR 248.9 million, aligning with forecasts.

The company's Ophthalmology Strategic Business Unit achieved growth of 8.5%, with revenue climbing to €1,724 million. This growth is complemented by strong performances in both equipment and consumables sales. The Microsurgery unit also reported positive results, with a revenue increase of 5.7% driven by new product deliveries.

Regionally, the EMEA area saw the most substantial rise with 12.5% growth, supported by increases in Germany and other markets. In contrast, the APAC region recorded modest growth, while Japan experienced a revenue decline.